B. Till

B. Sandmaier, D. Maloney, J. Pagel, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma

T. Gooley, O. Press, A. Gopal, 2018, Blood research.

Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.

R. Ermoian, M. Shadman, O. Press, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.

S. Smith, D. Maloney, J. Pagel, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

High‐dose CD20‐targeted radioimmunotherapy‐based autologous transplantation improves outcomes for persistent mantle cell lymphoma

D. Maloney, J. Pagel, J. Rajendran, 2015, British journal of haematology.

Brentuximab vedotin administered to platinum‐refractory, transplant‐naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status

D. Maloney, J. Pagel, O. Press, 2015, Hematological oncology.

Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.

D. Maloney, J. Pagel, K. Guthrie, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.

D. Maloney, J. Pagel, K. Guthrie, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study

Wan-Jen Hong, F. Morschhauser, M. Palomba, 2021, Clinical Lymphoma Myeloma and Leukemia.

Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade

E. Mostaghel, K. Edlefsen, S. Graf, 2020, British journal of haematology.

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma.

B. Hill, R. Lynch, M. Shadman, 2019, Clinical lymphoma, myeloma & leukemia.

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.

M. Sorror, B. Sandmaier, D. Maloney, 2019, Blood advances.

Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.

B. Miller, B. Sandmaier, J. Pagel, 2015, Blood.

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.

K. Wittrup, T. Gooley, D. Hamlin, 2018, Blood.

90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma

B. Sandmaier, J. Pagel, J. Rajendran, 2020, Bone Marrow Transplantation.

CD20-speciﬁc adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

D. Maloney, S. Riddell, P. Greenberg, 2012 .

Intravascular large B cell lymphoma presenting in a liver explant

S. Cherian, J. Fromm, M. Roshal, 2008, Journal of Clinical Pathology.

Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy

Yonghao Yang, Lingdi Zhao, Q. Gao, 2022, Cancer Immunology, Immunotherapy.

Eligibility for CAR T‐cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL

E. Warren, R. Lynch, C. Ujjani, 2019, American journal of hematology.

Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity

D. Maloney, B. Storer, J. Pagel, 2015, Leukemia & lymphoma.

Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma

D. Maloney, J. Pagel, T. Gooley, 2008, Leukemia & lymphoma.

Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells

Q. Gao, B. Till, Zibing Wang, 2017, Oncoimmunology.

Outcomes of patients with large B‐cell lymphomas and progressive disease following CD19‐specific CAR T‐cell therapy

D. Maloney, E. Warren, C. Turtle, 2019, American journal of hematology.

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma

J. Friedberg, J. Leonard, M. Leblanc, 2017, Journal of the National Cancer Institute.

Pegylated GCSF Can Be Used With First‐Line da‐EPOCH‐R Without Compromising Dose Intensity, Safety, or Efficacy

O. Press, R. Cassaday, A. Cowan, 2017, Clinical lymphoma, myeloma & leukemia.

Management of mantle cell lymphoma in the elderly.

Mitchell R. Smith, B. Till, P. Martin, 2012, Best practice & research. Clinical haematology.

Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies

X. Yan, Yonghao Yang, Lingdi Zhao, 2022, Frontiers in Immunology.

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma

J. Pagel, T. Gooley, O. Press, 2016, Bone Marrow Transplantation.

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas

D. Maloney, David Wu, O. Press, 2016, Bone Marrow Transplantation.

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

Jinjuan Wang, Brent L Wood, Xiaojun Qian, 2008, Blood.

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.

H. Heslop, G. Bauer, P. Marks, 2021, Blood cancer discovery.

Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.

H. Mirzaei, J. Hadjati, B. Till, 2016, Cancer letters.

Predictive and therapeutic biomarkers in chimeric antigen receptor T‐cell therapy: A clinical perspective

H. Mirzaei, H. Mirzaei, A. Namdar, 2018, Journal of cellular physiology.

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

T. Gooley, D. Hamlin, D. Wilbur, 2017, Cancer research.

Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma

S. Riddell, M. Jensen, O. Press, 2013, PloS one.

Role of fibrosarcoma-induced CD11b+ myeloid cells and tumor necrosis factor-α in B cell responses

X. Yan, Z. Qin, B. Till, 2022, Oncogene.

Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions

S. Heimfeld, S. Riddell, M. Jensen, 2018, Journal of immunotherapy.

Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.

D. Maloney, David Wu, O. Press, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The Alpha Emitter Astatine-211 Targeted to CD38 can Eradicate Multiple Myeloma in a Disseminated Disease Model.

B. Miller, B. Sandmaier, T. Gooley, 2019, Blood.

Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy

R. Lynch, M. Shadman, R. Cassaday, 2020, British journal of haematology.

Multicentre retrospective study of intravascular large B‐cell lymphoma treated at academic institutions within the United States

M. Kaminski, P. Boonstra, T. Phillips, 2019, British journal of haematology.

Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy

J Zhang, Yonghao Yang, Lingdi Zhao, 2022, Cancer Immunology, Immunotherapy.

Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma

Jun Wang, Yonghao Yang, Q. Gao, 2021, Frontiers in Oncology.

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.

H. Deeg, D. Maloney, E. Warren, 2019, Clinical lymphoma, myeloma & leukemia.

T-cell immunotherapy: looking forward.

D. Baltimore, A. Ribas, S. Rosenberg, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study

D. Maloney, C. Turtle, R. Lynch, 2022, Journal of cellular and molecular medicine.

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies.

M. Bar, D. Maloney, C. Turtle, 2020, Blood.

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

M. Bar, D. Maloney, E. Warren, 2020 .

High Efficacy and Low Toxicity of MB-106, a Third Generation CD20 Targeted CAR-T for Treatment of Relapsed/Refractory B-NHL and CLL

D. Maloney, E. Warren, C. Turtle, 2022, Transplantation and Cellular Therapy.

Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma

D. Maloney, C. Turtle, R. Lynch, 2022, Leukemia & lymphoma.

Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma

D. Maloney, C. Turtle, H. Kiem, 2020 .

T-Cell Immunotherapy: Looking Forward: T Cell Immunotherapy: Optimizing Trial Design Bethesda, Maryland 10-11 September 2013.

D. Baltimore, A. Ribas, S. Rosenberg, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA

B. Sandmaier, K. Wittrup, J. Pagel, 2020, Molecular Cancer Therapeutics.

Construction and functional characterization of a fully human anti‐CD19 chimeric antigen receptor (huCAR)‐expressing primary human T cells

H. Mirzaei, E. Masoumi, F. Noorbakhsh, 2018, Journal of cellular physiology.

Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma

B. Wood, D. Maloney, F. Appelbaum, 2018, Blood.

Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.

K. Wittrup, T. Gooley, D. Hamlin, 2016, Cancer research.

Downmodulation Lysis and Its Impairment by TCR Triggering Predicts the Magnitude of Target Mathematical Modeling of Chimeric TCR

P. Greenberg, S. Forman, M. Jensen, 2010 .

T Cell Immunotherapy: Optimizing Trial Design

D. Baltimore, A. Ribas, S. Rosenberg, 2014 .

CD 20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD 28 and 4-1 BB domains : pilot clinical trial results

D. Maloney, S. Riddell, P. Greenberg, 2012 .

Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma

B. Till, 2018, Current Treatment Options in Oncology.

Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy

D. Maloney, E. Warren, C. Turtle, 2018, Blood.

BCNU-associated pneumonitis: portrait of a toxicity

D. Madtes, B. Till, 2012, Leukemia & lymphoma.

Phase II trial of R‐CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601

Sonali M. Smith, J. Friedberg, L. Rimsza, 2016, British journal of haematology.

Impact of double/triple hit pathology on rates and durability of RT response among patients with relapsed/refractory large B-cell lymphoma.

K. Russell, E. Warren, R. Lynch, 2019, Practical radiation oncology.

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

A. Goy, M. Palomba, E. Penuel, 2015 .

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

B. Wood, D. Maloney, C. Turtle, 2019, Blood.

Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients

X. Yan, Q. Gao, Huijuan Wang, 2022, Cancer Immunology, Immunotherapy.

Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes

D. Maloney, C. Turtle, H. Kiem, 2019, Blood.

CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas

D. Maloney, E. Warren, C. Turtle, 2019, Blood.

Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

B. Wood, D. Maloney, C. Turtle, 2021, Blood.

Response to paclitaxel in adenoid cystic carcinoma of the salivary glands

R. Martins, B. Till, 2008, Head & neck.

A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB COMBINED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMA (NHL)

F. Morschhauser, M. Palomba, G. Cartron, 2017 .

The Mantle Cell Lymphoma International Prognostic Index (MIPI) at Diagnosis Is Associated with Survival of Mantle Cell Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.

D. Maloney, J. Pagel, K. Guthrie, 2008 .

Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression

R. Lynch, M. Shadman, R. Cassaday, 2020 .

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

J. Friedberg, J. Leonard, T. Witzig, 2019, Blood.

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma.

A. Alizadeh, E. Warren, R. Lynch, 2021, Blood.

Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Safety and Efficacy of Escalating Doses of 90 Y-BC8-DOTA (Anti-CD45) Followed by Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Chemotherapy and Autologous Stem Cell Transplantation (ASCT) for High-Risk Lymphoma

D. Maloney, J. Pagel, J. Rajendran, 2018 .

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

J. Friedberg, J. Leonard, N. Bartlett, 2021 .

PEMBROLIZUMAB WITH RCHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL AND GRADE 3B FOLLICULAR LYMPHOMA: FINAL RESULTS OF A PHASE I TRIAL

R. Lynch, R. Cassaday, A. Cowan, 2019, Hematological Oncology.

Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy

Yongping Song, B. Till, Zibing Wang, 2020, Frontiers in Immunology.

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL

D. Maloney, C. Turtle, H. Kiem, 2023, Blood advances.

Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation.

D. Maloney, J. Pagel, K. Guthrie, 2012 .

Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601

J. Friedberg, L. Rimsza, R. Fisher, 2014 .

BCNU-associated pneumonitis: portrait of a toxicity

D. Madtes, B. Till, 2012, Leukemia & lymphoma.

γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.

D. Maloney, C. Turtle, S. Riddell, 2023, The Lancet. Oncology.

CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype

Ryan S Basom, B. Till, M. Shadman, 2023, Journal for ImmunoTherapy of Cancer.